Sugi Predict

Sugi Predict / Compounds / SCHEMBL372259

SCHEMBL372259

SCHEMBL372259

COc1cc2nc(C)nc(Cl)c2cc1OC

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE4A P27815 3/20 0.54
▸ PDE4D Q08499 3/20 0.54
▸ KRAS P01116 2/20 0.50
▸ SOS1 Q07889 2/20 0.50
▸ EGFR P00533 1/20 0.50
▸ ENPP1 P22413 2/20 0.47
▸ PDE3B Q13370 2/20 0.47
▸ PDE3A Q14432 2/20 0.47
▸ PGK1 P00558 1/20 0.46
▸ FBP1 P09467 1/20 0.46
▸ NQO2 P16083 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ WHR1 P49842 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29723105 1.00 PDE4A (0.54) PDE4APDE4DKRASSOS1EGFR
SCHEMBL23004817 0.89 PDE4A (0.44) PDE4APDE4DKRASSOS1EGFR
SCHEMBL20511938 0.89 PDE4A (0.44) PDE4APDE4DKRASSOS1EGFR
SCHEMBL28486664 0.87 PDE4A (0.47) PDE4APDE4DKRASSOS1EGFR
SCHEMBL23520763 0.86 PDE4A (0.42) PDE4APDE4DKRASSOS1EGFR
SCHEMBL23521048 0.86 PDE4A (0.42) PDE4APDE4DKRASSOS1EGFR
SCHEMBL28496073 0.86 PDE4A (0.49) PDE4APDE4DKRASSOS1EGFR
SCHEMBL23520712 0.86 PDE4A (0.42) PDE4APDE4DKRASSOS1EGFR
Hydrochloric Acid SCHEMBL29127441 0.85 PDE4A (0.46) PDE4APDE4DKRASSOS1EGFR
SCHEMBL20509231 0.83 ELANE (0.55) KRASSOS1EGFRENPP1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4737453-A1 NOVEL SELENOPHENE DERIVATIVES Aigen Sciences Inc. (KR) 2026-05-06 — — EP disclosed
US-20260022135-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF 1CBIO INC (US) 2026-01-22 — — US disclosed
US-12325720-B2 Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof 1CBIO, INC. (US) 2025-06-10 — — US disclosed
WO-2025005748-A1 NOVEL SELENOPHENE DERIVATIVES (주)아이젠사이언스 2025-01-02 — — WO disclosed
US-20240352046-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF 1CBIO INC (US) 2024-10-24 — — US disclosed
US-20240262822-A1 WDR5 INHIBITORS AND MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2024-08-08 — — US disclosed
US-20240083857-A1 2-Methyl-Quinazolines Bayer Pharma AG (DE) 2024-03-14 — — US disclosed
EP-4334305-A1 WDR5 INHIBITORS AND MODULATORS Vanderbilt University (US) 2024-03-13 — — EP disclosed
CN-117510513-A Heterocyclic compounds having biological activity 首药控股(北京)股份有限公司 2024-02-06 — — CN disclosed
WO-2024022244-A1 HETEROCYCLIC COMPOUND HAVING BIOLOGICAL ACTIVITY 首药控股(北京)股份有限公司 2024-02-01 — — WO disclosed
WO-2005030140-A2 C-MET MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-04-07 — — WO disclosed
US-5658917-A ANTIINFLAMMATION AGENT KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-08-19 — — US disclosed
US-5648353-A INFLAMMATORY EDEMA KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-07-15 — — US disclosed
EP-0782570-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1997-07-09 — — EP disclosed
US-5624926-A Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-04-29 — — US disclosed
US-5605900-A USEFUL FOR TREATMENT OF INFLAMMATORY EDEMA, ISCHEMIA AND REPERFUSION DISORDERS KYOWA HAKKO KOGYO CO., LTD. (JP) 1997-02-25 — — US disclosed
WO-1996009294-A1 SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE THE WELLCOME FOUNDATION LIMITED (GB) 1996-03-28 — — WO disclosed
EP-0638567-A1 ADENOSINE INCORPORATION INHIBITOR KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1995-02-15 — — EP disclosed
US-4546102-A CARDIOTONIC AGENTS BOEHRINGER INGELHEIM KG (DE) 1985-10-08 — — US disclosed
EP-0108981-A1 Semicarbazides, their preparation and use BOEHRINGER INGELHEIM KG (DE) 1984-05-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240083857-A1 2-Methyl-Quinazolines NRAS, KRAS, KSR2 PDE4A 3305/4885PDE4D 3530/4885KRAS 2/4885
US-20240262822-A1 WDR5 INHIBITORS AND MODULATORS WDR5, WDR1, WDR3 PDE4A 4115/4885PDE4D 4314/4885KRAS 1352/4885
US-20260022135-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, NCEH1 PDE4A 264/4885PDE4D 903/4885KRAS 3261/4885
US-20240352046-A1 ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF ENPP1, ENPP3, ENPP2 PDE4A 17/4885PDE4D 35/4885KRAS 3418/4885
US-12325720-B2 Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof ENPP1, ENPP3, ENPP2 PDE4A 17/4885PDE4D 35/4885KRAS 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.